CTOs on the Move

Microline Surgical

www.microlinesurgical.com

 
Microline Surgical develops and manufactures high precision open and laparoscopic surgical instruments. Microline`s laparoscopic reposable instruments provide a cost-effective and eco-friendly solution for today`s OR. The MiFusion product line offers a broad spectrum of open and laparoscopic instruments used to seal and divide tissue utilizing proprietary Thermal Fusion technology.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Pharmaceutical Search Professionals Inc

Pharmaceutical Search Professionals Inc is a North Wales, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PBN Pharma

PBN Pharma is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Walgreen Co

Walgreen Co is a Deerfield, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Centura Health

Centura Health connects individuals, families and neighborhoods across Colorado and western Kansas with more than 6,000 physicians and 21,000 of the best hearts and minds in health care. Through our 19 hospitals, neighborhood health centers, physician practices and clinics, home care and hospice services, and Flight For Life® Colorado, our caregivers make the region`s best health care accessible. We`re on a mission to build flourishing communities and whole person care. We`re Centura Health, and we`re your dedicated health partner for life.

Silence Therapeutics

Our 20-plus years of RNAi experience together with our validated mRNAi GOLD™ platform make us a partner of choice for pharmaceutical companies looking to access the benefits of the siRNA and add this revolutionary modality to their discovery pipeline. As pioneers in the design and development of siRNAs (short interfering RNAs), Silence Therapeutics is advancing a new generation of medicines to potentially address the needs of patients who have limited or inadequate treatment options. Our mission is to use our technology to create a new generation of therapeutics which can improve outcomes for patients and, in the process, build shareholder value. We are developing a deep pipeline of innovative siRNAs based on our mRNAi GOLD™ platform for diseases with a genetic basis. The depth and versatility of our liver-targeting technology gives us the opportunity to address a wide range of conditions in virtually any therapeutic area.